A Phase 3 interventional study of Denosumab and Placebo in Osteoporosis, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 4 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-12.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 24 in phase 3, and was the 12th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,262 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Daiichi Sankyo Co., Ltd., one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
Daiichi Sankyo has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
Drug: Denosumab
Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
Drug: Placebo
Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
Drug: Alendronate sodium hydrate
Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Oral tablet once a week for 24 months
Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo
Time frame: Baseline to 24 months
The Percentage of Non-vertebral Fractures
The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures
Time frame: Baseline to 24 Months
Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.
The results are expressed as a percentage by Kaplan-Meier estimate.
Time frame: Baseline to 24 Months
| Milestone | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| Started | 500 | 511 | 251 |
| Completed | 414 | 416 | 204 |
| Not completed | 86 | 95 | 47 |
| Vertebral fractures | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo | 3.6 (2.2 to 5.8) | 10.3 (7.8 to 13.5) | 7.2 (4.6 to 11.4) |
The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures
| percentage of participants | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| The Percentage of Non-vertebral Fractures | 4.1 (2.6 to 6.6) | 4.1 (2.6 to 6.5) | 2.7 (1.2 to 5.9) |
The results are expressed as a percentage by Kaplan-Meier estimate.
| percentage of participants | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo. | 0.0 (0.0 to 0.0) | 0.5 (0.1 to 1.9) | 0.0 (0.0 to 0.0) |
Collected over Baseline to 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab | — | 65/475 (13.7%) | 475/475 (100%) |
| Placebo | — | 68/481 (14.1%) | 481/481 (100%) |
| Alendronate | — | 30/242 (12.4%) | 242/242 (100%) |
| Event | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| CataractEye disorders | 2/475 | 7/481 | 5/242 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/475 | 1/481 | 3/242 |
| Colonic polypGastrointestinal disorders | 1/475 | 5/481 | 1/242 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 4/475 | 0/481 | 1/242 |
| PneumoniaInfections and infestations | 0/475 | 1/481 | 2/242 |
| VertigoEar and labyrinth disorders | 1/475 | 0/481 | 2/242 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 3/475 | 3/481 | 1/242 |
| Subarachnoid haemorrhageNervous system disorders | 3/475 | 1/481 | 0/242 |
| Cerebral infarctionNervous system disorders | 3/475 | 0/481 | 0/242 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/475 | 3/481 | 0/242 |
| Event | Denosumab | Placebo | Alendronate |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 211/475 | 203/481 | 93/242 |
| ContusionInjury, poisoning and procedural complications | 80/475 | 74/481 | 54/242 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 77/475 | 43/481 | 37/242 |
| Dental cariesGastrointestinal disorders | 73/475 | 64/481 | 29/242 |
| Back painMusculoskeletal and connective tissue disorders | 69/475 | 60/481 | 28/242 |
| ConstipationGastrointestinal disorders | 49/475 | 37/481 | 21/242 |
| PeriodontitisGastrointestinal disorders | 41/475 | 27/481 | 16/242 |
| EczemaSkin and subcutaneous tissue disorders | 39/475 | 41/481 | 16/242 |
| HypertensionVascular disorders | 39/475 | 36/481 | 11/242 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 38/475 | 30/481 | 17/242 |
The demography information shows the number of participants included in the full analysis set (FAS) for efficacy analyses, which includes all randomized subjects except for those who did not have osteoporosis, did not receive the investigational product, or had no available efficacy data after the first dose of the investigational product.
| Age, Continuous(years) | Denosumab | Placebo | Alendronate | Total |
|---|---|---|---|---|
| Mean | 69.9 ± 7.36 | 69.0 ± 7.67 | 70.2 ± 7.31 | 69.6 ± 7.49 |
| Sex: Female, Male(Participants) | Denosumab | Placebo | Alendronate | Total |
|---|---|---|---|---|
| Female | 449 | 456 | 230 | 1135 |
| Male | 23 | 24 | 12 | 59 |
| Region of Enrollment(participants) | Denosumab | Placebo | Alendronate | Total |
|---|---|---|---|---|
| Japan | 472 | 480 | 242 | 1194 |
| the number of participants with vertebral fractures(Participants) | Denosumab | Placebo | Alendronate | Total |
|---|---|---|---|---|
| Number | 466 | 471 | 237 | 1174 |
The record gives a start of May 2008, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab